16th International Conference on Malignancies in HIV/AIDS

166 Pages·2017·8.24 MB·English

16th International Conference on
Malignancies in HIV/AIDS
October 23-24, 2017
Lister Hill Center Auditorium
NIH Main Campus
Bethesda, Maryland
O˜ce of HIV and AIDS Malignancy | National Cancer Institute
National Institutes of Health | U.S. Department of Health and Human Services
PROGRAM

Day 1: October 23

7:45. a.m. - 5:30 p.m. Registration

8:00 a.m. - 8:30 a.m. Day 1 Poster Setup
Travel Awardee Posters will stay up for the entire meeting.

8:30 a.m. - 8:45 a.m. Opening Remarks
Geraldina Dominguez, Ph.D.
National Cancer Institute, NIH

8:45 a.m. - 9:00 a.m. Welcome
Robert Yarchoan, M.D.
National Cancer Institute, NIH

9:00 a.m. - 10:30 a.m. Session 1: HPV and Cervical Cancer
Moderators: Joel Palefsky, M.D.
University of California, San Francisco

Mark H. Einstein, M.D.
Rutgers University

9:00 a.m. - 9:30 a.m. P1. HPV/Vaccine Trial
Douglas R. Lowy, M.D.
National Cancer Institute, NIH

9:30 a.m. - 10:00 a.m. P2. Cervical Cancer Control in Africa
Hennie Botha, MBChB, M.Med, FCOG, Ph.D.
Stellenbosch University

10:00 a.m. - 10:30 a.m. P3. Molecular Carcinogenesis of Cervical Cancer: Beyond HPV
Nicolas Wentzensen, M.D., Ph.D.
National Cancer Institute, NIH

10:30 a.m. - 11:00 a.m. Break and Poster Viewing

11:00 a.m. - 12 noon Session 2: Gene Therapy and Stem Cell Transplantation
Moderator: Thomas S. Uldrick, M.D.
National Cancer Institute, NIH

11:00 a.m. - 11:30 a.m. P4. HIV Gene Therapy
Hans-Peter Kiem, M.D., Ph.D.
Fred Hutchinson Cancer Research Center

11:30 a.m. - 12 noon P5. Hematopoietic Transplantation for Patients With HIV and Hematologic
Malignancies
Richard F. Ambinder, M.D., Ph.D.
Johns Hopkins University School of Medicine

12 noon - 1:00 p.m. Lunch (on your own or lunch boxes)

- 1 -
1:00 p.m. - 2:00 p.m. Day 1 Poster Viewing (Presenters stand by their posters.)

2:00 p.m. - 3:00 p.m. Session 3: Epstein-Barr Virus and Rhesus Rhadinovirus
Moderators: Ethel Cesarman, M.D., Ph.D.
Weill Cornell Medical College

Erle S. Robertson, Ph.D.
Perelman School of Medicine, University of Pennsylvania

2:00 p.m. - 2:15 p.m. O1. Development of an EBNA1 Inhibitor for the Treatment of HIV-Associated
Epstein-Barr Virus-Driven Malignancies
Troy E. Messick, Ph.D.
The Wistar Institute

2:15 p.m. - 2:30 p.m. O2. Tumor Epstein-Barr Virus Status Is Prognostic in Primary Effusion
Lymphoma
Kathryn Lurain, M.D.
National Cancer Institute, NIH

2:30 p.m. - 2:45 p.m. O3. Cell Receptor Activation Triggers Caspase-Mediated Cleavage of PIAS1
to Facilitate Epstein-Barr Virus Lytic Replication
Renfeng Li, Ph.D.
Philips Institute for Oral Health Research

2:45 p.m. - 3:00 p.m. O4. Anti-IL-15-Mediated Depletion of NK Cells in Primary SIV Infection Does
Not Alter SIV Replication but Accelerates Rhesus Rhadinovirus
Pathogenesis
Afam A. Okoye, Ph.D.
Oregon Health & Science University

3:00 p.m. - 3:30 p.m. Break and Poster Viewing

3:30 p.m. - 5:45 p.m. Session 4: KSHV and Kaposi Sarcoma
Moderators: Dirk Dittmer, Ph.D.
The University of North Carolina at Chapel Hill

Paul M. Lieberman, Ph.D.
The Wistar Institute

3:30 p.m. - 4:00 p.m. P6. KSHV Targets Nuclear Export of mRNA to Regulate Host Gene
Expression
Ting-Ting Wu, Ph.D.
University of California, Los Angeles

4:00 p.m. - 4:15 p.m. O5. Manipulation of the Host Iron Regulon by Kaposi Sarcoma Herpesvirus
(KSHV)
Ashlee V. Moses, Ph.D.
Oregon Health & Science University

4:15 p.m. - 4:30 p.m. O6. Modulation of Cholesterol Pathway in KSHV Infection
Anna Serquiña, M.D., Ph.D.
National Cancer Institute, NIH

- 2 -
4:30 p.m. - 4:45 p.m. O7. Portable Nucleic Acid Amplification Testing as a Means for Diagnosis
of Kaposi Sarcoma in Africa
Jeffrey N. Martin, M.D., M.P.H.
University of California, San Francisco

4:45 p.m. - 5:00 p.m. O8* Kaposi Sarcoma-Associated Herpesvirus (KSHV) Seroprevalence and
Antibody Levels in Relation to Haemoglobin and Malaria Among
Individuals From Rural Uganda
Angela Nalwoga, M.Sc. (Ph.D. candidate)
MRC/UVRI Uganda Research Unit on AIDS

5:00 p.m. - 5:15 p.m. O9. T-cell Receptor Sequencing of Tumor-Infiltrating Lymphocytes in
Kaposi Sarcoma Tumors Identifies Candidate Tumor-Reactive T-cell
Responses
Warren Phipps, M.D., M.PH.
Fred Hutchinson Cancer Research Center

5:15 p.m. - 5:30 p.m. O10. Exploring the Function and Mechanism of Pomalidomide-Induced
Increases in Immune Surface Markers in Primary Effusion Lymphoma Cells
David A. Davis, Ph.D.
National Cancer Institute, NIH

5:30 p.m. - 5:45 p.m. O11. AMC-070: Lenalidomide Is Safe and Effective in AIDS-Associated
Kaposi Sarcoma
Dirk Dittmer, Ph.D.
The University of North Carolina at Chapel Hill

5:45 p.m. End of Day 1

08* is a travel awardee.

- 3 -
Day 2: October 24

8:00 a.m. - 8:15 a.m. Day 2 Poster Setup and Viewing

8:15 a.m. - 8:30 a.m. Welcome Day 2
Geraldina Dominguez, Ph.D.
National Cancer Institute, NIH

8:30 a.m. - 10:00 a.m. Session 5: Clinical Research and Trials
Moderators: Lee Ratner, M.D., Ph.D.
Washington University School of Medicine in St. Louis

Richard F. Little, M.D.
National Cancer Institute, NIH

8:30 a.m. - 9:00 a.m. P7. Development of HIV-Specific T-Cell Therapy: Lessons From Epstein-
Barr Virus
Catherine Bollard, MBChB
Children’s Research Institute

9:00 a.m. - 9:30 a.m. P8. As-Needed Versus Immediate Etoposide Chemotherapy in Combination
With Antiretroviral Therapy for Mild or Moderate AIDS-Associated Kaposi
Sarcoma in Resource-Limited Settings: A5264/AMC-067
Thomas Campbell, M.D., Ph.D.
University of Colorado

9:30 a.m. - 9:45 a.m. O12. Cisplatin and Radiation Therapy in HIV-Infected Women With Locally
Advanced Cervical Cancer in Sub-Saharan Africa (AMC-081)
Mark H. Einstein, M.D., M.S.
Rutgers New Jersey Medical School

9:45 a.m. - 10:00 a.m. O13. Extracellular Vesicles Derived From HIV-Infected T Cells Promote
Progression of Non-AIDS-Defining Cancers
Ge Jin, Ph.D.
Case Western Reserve University

10:00 a.m. - 10:30 a.m. Break and Poster Viewing

10:30 a.m. - 12 noon Session 6: Epidemiology and Screening
Moderators: Gypsyamber D’Souza. Ph.D.
Johns Hopkins Bloomberg School of Public Health

Elizabeth Chiao, M.D., M.P.H.
Baylor College of Medicine

10:30 a.m. - 11:00 a.m. P9. Projected Cancer Incidence and Burden in HIV-Infected Adults in the
United States Through 2030
Meredith S. Shiels, Ph.D.
National Cancer Institute, NIH

- 4 -
11:00 a.m. - 11:15 a.m. O14. Elevated Risk of First and Second Primary Cancers Among People
With HIV
Nancy A. Hessol, M.S.P.H.
University of California, San Francisco

11:15 a.m. - 11:30 a.m. O15. Lung Cancer Mortality Among People Living With HIV in the United
States: Impact of Smoking and Smoking Cessation
Krishna P. Reddy, M.D.
Massachusetts General Hospital

11:30 a.m. - 11:45 a.m. O16. Prevention and Early Detection of Cervical Cancer in Africa Through
Community-Based Self-Administered Screening and Mobile Treatment
Provision
Miriam Nakalembe, MBChB, Ph.D.
Infectious Diseases Institute, Makerere University

11:45 a.m. - 12 noon O17. Persistent Anal HPV16/18 Infections as Predictors of High-Grade Anal
Lesions in Older MSM
Hilary K. Hsu, M.P.H.
University of California, Los Angeles

12 noon - 1:00 p.m. Lunch (on your own or lunch boxes)

1:00 p.m. - 2:00 p.m. Day 2 Poster Viewing (Presenters stand by their posters.)

2:00 p.m. - 3:30 p.m. Session 7: Polyomaviruses and Immunotherapy
Moderators: Thomas G. Gross, M.D., Ph.D.
National Cancer Institute, NIH

Corey Casper, M.D., M.P.H.
Fred Hutchinson Cancer Research Center

2:00 p.m. - 2:30 p.m. P10. BK Polyomavirus, APOBEC3B, and Cancer: Molecular Judo Gone
Awry?
Christopher Buck, Ph.D.
National Cancer Institute, NIH

2:30 p.m. - 3:00 p.m. P11. PD-L1 Inhibition and the Evolving Management of Merkel Cell
Carcinoma
Isaac F. Brownell, M.D., Ph.D.
National Cancer Institute, NIH

3:00 p.m. - 3:15 p.m. O18*. A Case Series of Nivolumab in Veterans With HIV Infection and
Malignancy
Elaine Chang, M.D.
Baylor College of Medicine

3:15 p.m. - 3:30 p.m. O19. AMS095: A Phase I Study of Ipilimumab (Ipi) and Nivolumab (Nivo) in
Advanced HIV-Associated Solid Tumors (Preliminary Findings)
Lakshmi N. Rajdev, M.D.
Albert Einstein College of Medicine and Montefiore Medical Center

3:30 p.m. - 4:00 p.m. Break and Poster Viewing

- 5 -
4:00 p.m. - 5:25 p.m. Session 8: Pathogen Host Interactions
Moderators: Jennifer Webster-Cyriaque, Ph.D., D.D.S.
The University of North Carolina at Chapel Hill

Otoniel Martinez-Maza, Ph.D.
University of California, Los Angeles

4:00 p.m. - 4:20 p.m. P12. Epstein-Barr Virus and Malaria Profiles in African Burkitt Lymphoma:
What Can We Learn From Array-Based Studies?
Sam Mbulaiteye, M.D.
National Cancer Institute, NIH

4:20 p.m. - 4:35 p.m. O20. A Prospective Study of Serum Microbial Translocation and
Inflammation-Associated Biomarkers and Risk of AIDS-Related Non-
Hodgkin Lymphoma
Marta Epeldegui, Ph.D.
University of California, Los Angeles

4:35 p.m. - 4:50 p.m. O21. Identifying Transcriptional and Prognostic Biomarkers of HIV-
Associated Diffuse Large B-cell Lymphoma From Malawi
Yuri Fedoriw, M.D.
The University of North Carolina at Chapel Hill

4:50 p.m. - 5:10 p.m. P13. KSHV and Co-infections
Denise Whitby, Ph.D.
Frederick National Laboratory for Cancer Research, NIH

5:10 p.m. - 5:25 p.m. O22. Strategies to Improve Kaposi Sarcoma Outcomes in Zimbabwe: A
Community-Based Clinical Trial of a Training Intervention for Improved
Primary Care of AIDS-KS (SIKO study)
Margaret Borok, M.D.
University of Zimbabwe College of Health Sciences

5:25 p.m. - 5:35 p.m. Closing Comments
Robert Yarchoan, M.D.
National Cancer Institute, NIH

5:35 p.m. Meeting Adjourned

019* is a travel awardee.

- 6 -
PROGRAM COMMITTEE

PROGRAM CO-CHAIRS Corey Casper, M.D., M.P.H.
Professor of Medicine, Epidemiology and Global
Geraldina Dominguez, Ph.D. Health
Director University of Washington
AIDS Malignancy Program Full Member, Vaccine and Infectious Diseases
Office of HIV and AIDS Malignancy Clinical Research and Public Health Sciences
National Cancer Institute Divisions
National Institutes of Health Fred Hutchinson Cancer Research Center
Building 31, Suite 3A-33 M1-B140
31 Center Drive 1100 Fairview Avenue, North
Bethesda, MD 20892-2440 Seattle, WA 98109
[phone] [phone]
[email protected] [email protected]

Robert Yarchoan, M.D. Ethel Cesarman, M.D., Ph.D.
Director Professor
Office of HIV and AIDS Malignancy Pathology and Laboratory Medicine
Chief, HIV and AIDS Malignancy Branch Weill Cornell Medical College
Center for Cancer Research 1300 York Avenue
National Cancer Institute New York, NY 10065
National Institutes of Health [phone]
Building 10, Room 6N-106 [email protected]
10 Center Drive
Bethesda MD 20892-1868 Elizabeth Y. Chiao, M.D., M.P.H.
[phone] Associate Professor
[email protected] Baylor College of Medicine
BCM286
PROGRAM COMMITTEE One Baylor Plaza
Houston, TX 77030
Richard F. Ambinder, M.D., Ph.D. (713) 794-8666
Director, Division of Hematologic Malignancies [email protected]
Professor of Oncology [email protected]
The Johns Hopkins University School of Medicine
Bunting-Blaustein Building, Room 390 Dirk Dittmer, Ph.D.
1650 Orleans Street Professor
Baltimore, MD 21287 Department of Microbiology and Immunology
[phone] Center for AIDS Research
[email protected] Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Room12-046
450 West Drive
Chapel Hill, NC 27599-7295
[phone]
[email protected]

- 7 -
Gypsyamber D’Souza, Ph.D. Johnan Kaleeba, Ph.D.
Associate Professor Program Director
Department of Epidemiology Office of HIV and AIDS Malignancy
Johns Hopkins Bloomberg School of Public Health National Cancer Institute
Room E6132B National Institutes of Health
615 North Wolfe Street Building 31, Room 3A33
Baltimore, MD 21205 31 Center Drive
[phone] Bethesda, MD 20892-2440
[email protected] [phone]
[email protected]
Mark H. Einstein, M.D., M.S.
Professor and Chair, Department of Obstetrics, Paul M. Lieberman, Ph.D.
Gynecology and Women's Health Hilary Koprowski, M.D., Endowed Professor
Rutgers New Jersey Medical School The Wistar Institute
Medical Science Building 3601 Spruce Street
Room E-506 Philadelphia, PA 19104
185 South Orange Avenue [phone]
Newark, NJ 07101 [email protected]
[phone]
[email protected] Richard F. Little, M.D.
Head, Hematologic, HIV, and Stem Cell Therapeutics
Eric A. Engels, M.D., M.P.H. Clinical Investigations Branch
Senior Investigator National Cancer Institute
Division of Cancer Epidemiology and Genetics National Institutes of Health
National Cancer Institute Room 5W426
National Institutes of Health 609 Medical Center Drive
Room 6E226 Rockville, MD 20850
9609 Medical Center Drive [phone]
Rockville, MD 20850 [email protected]
[phone]
[email protected] Otoniel Martinez-Maza, Ph.D.
Professor
Thomas G. Gross, M.D., Ph.D. David Geffen School of Medicine
Deputy Director of Science Fielding School of Public Health
Center for Global Health AIDS Institute
National Cancer Institute Jonsson Comprehensive Cancer Center
National Institutes of Health Director
Room 3W534 Basic and Translational Sciences Program Section
9609 Medical Center Drive UCLA Center for AIDS Research
Rockville, MD 20850 University of California, Los Angeles
[phone] BSRB 173
[email protected] 615 Charles Young Drive
Los Angeles, CA 90095
Rebecca Liddell Huppi, Ph.D. [phone]
Program Director [email protected]
Office of HIV and AIDS Malignancy
National Cancer Institute
National Institutes of Health
Building 31, Room 3A-33
31 Center Drive
Bethesda, MD 20892-2440
[phone]
[email protected]

- 8 -
Sam M. Mbulaiteye, M.D. Elizabeth Read-Connole, Ph.D.
Senior Investigator Program Director, Viral Oncogenesis
Division of Cancer Epidemiology and Genetics Cancer Etiology Section Chief
National Cancer Institute Cancer Immunology, Hematology, and Etiology
National Institutes of Health Branch
Room 6E118 Division of Cancer Biology
9609 Medical Center Drive National Cancer Institute
Rockville, MD 20850 National Institutes of Health
[phone] Room 6W534
[email protected] 9609 Medical Center Drive
Rockville, MD 20850-9748
Ashlee V. Moses, Ph.D. [phone]
Professor [email protected]
Vaccine and Gene Therapy Institute
Oregon Health & Science University Erle S. Robertson, Ph.D.
505 NW 185th Avenue Vice Chair, Otorhinolaryngology-Head and Neck
Beaverton, OR 97006 Surgery
[phone] Endowed Professor of Otorhinolaryngology
[email protected] Professor of Microbiology
Perelman School of Medicine
Mostafa Nokta, M.D., Ph.D. Director
Director Tumor Virology Training Program
AIDS Cancer Clinical Program Associate Director of Global Cancer Research
Office of HIV and AIDS Malignancy Abramson Cancer Center
National Cancer Institute 3610 Hamilton Walk
National Institutes of Health 201 East Johnson Pavilion
Building 31, Room 3A-33 University of Pennsylvania
31 Center Drive Philadelphia, PA 19104
Bethesda, MD 20892-2440 [phone]
[phone] [email protected]
[email protected]
Michael J. Silverberg, Ph.D., M.P.H.
Joel Palefsky, M.D., FRCP(C) Research Scientist
Professor of Medicine Division of Research
University of California, San Francisco Kaiser Permanente
Box 0126 5th Floor
M-1203 2000 Broadway
505 Parnassus Oakland, CA 94612
San Francisco, CA 94118 [phone]
[phone] [email protected]
[email protected]
Ren Sun, Ph.D.
Lee Ratner, M.D., Ph.D. Professor
Professor University of California, Los Angeles
Department of Medicine 650 Charles E Young Drive, South
Oncology Division 10-155 Factor Building
Washington University School of Medicine in St. Louis Los Angeles, CA 90095
McDonnell Medical Sciences Building, Room 562 [phone]
St. Louis, MO 63110 [email protected]
[phone]
[email protected]

- 9 -